September 8, 2019
This feature highlights changes in clinical research organizations’ personnel.
Accent Therapeutics has appointed Shakti Narayan chief executive officer. Narayan was most recently chief business officer at Tango Therapeutics.
Kimberly Bone was named vice president of the medical and clinical affairs division at Aprecia. Bone previously spent 13 years working for Publix Super Markets where she served as clinical pharmacist, retail pharmacy manager and manager of managed care.
Nihar Bhakta has been named chief medical officer at Aristea Therapeutics. Bhakta was previously project team leader at Gossamer Bio.
Marianne De Backer has been named head of business development & licensing of the pharmaceuticals division at Bayer. De Backer previously led business development activities across different therapeutic areas and geographies at Johnson & Johnson.
Beam Therapeutics has named Terry-Ann Burrell as chief financial officer. Burrell was most recently at J.P. Morgan, where she was a managing director in the healthcare investment banking group.
BioMatrix Specialty Pharmacy
BioMatrix Specialty Pharmacy has appointed Nick Karalis chief executive officer. Karalis was the chief operating officer of BioMatrix Specialty Pharmacy, and founder of Elwyn Pharmacy group that became part of BioMatrix in 2017.
Randall Schatzman has been named chief executive officer at Bolt Therapeutics, Inc. Schatzman most recently served as president and CEO of Alder BioPharmaceuticals, Inc.
Cardinal Analytx Solutions
Cardinal Analytx Solutions has named Ryan Tarzy chief commercial officer. Previously, Tarzy served as the head of strategy and business at CoverMyMeds.
Cook Medical has appointed Rose Kelly-Falls global leader of procurement and supply chain. Previously, Kelly-Falls was vice president of sourcing and customer engagement at Proxima Group.
David Garrett has been named chief financial officer at Dynacure. Garrett was most recently vice president, corporate controller and head of investor relations at Nabriva Therapeutics, Inc.
Genfit has appointed Pascal Prigent as chief executive officer. Previously, Prigent served as the executive vice president of marketing and commercial development at Genfit.
Jack Hu has been named chief financial officer and chief strategy officer of Genor Biopharma. Hu’s most recently appointment was with Deutsche Bank, where he was head of APAC healthcare research.
Harmonic Bionics has appointed Christopher Prentice chief executive officer of Austin, Texas-based Harmonic Bionics. Prentice previously served as head of commercial integration at Medtronic.
Invicro, a Konica Minolta company, named Hidenori Seshimo vice president of biomarker services for Japan. Seshimo most recently served as representative director and regional vice president of business development for Bioclinica Japan K.K.
Kadmom has announced that Gregory Moss has been named executive vice president and chief compliance officer. Previously, Moss served as senior vice president at Kadmom.
Kayentis has appointed Estelle Haenel as medical director in France. Previously, Haenel served as the clinical pharmacology early development strategy lead.
Locate Bio has named John von Benecke chief financial officer and chief operating officer. Previously, Benecke served as the chief financial officer at Creavo Medical Technologies and Veryan Medical.
Søren Bregenholt has been named chief executive officer at Macrophage Pharma Limited. Bregenholt previously served as chief operating officer at Symphogen.
Johannes Levin has been appointed chief medical officer at MODAG. Levin is a group leader in the Neurodegenerative Diseases Group of the Department of Neurology of the Ludwig Maximilian University of Munich and at the German Center for Neurodegenerative Diseases.
Orbis International has named Danusia Dzierzbinski chief financial officer. Dzierzbinski most recently served as the deputy chief financial officer at the International Rescue Committee.
OMEICOS Therapeutics has appointed Simon Russell as chief business officer. Russell most recently co-founded Synendos Therapeutics.